HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsui, J. K.C. Articles by Calne, D. B. Search for Related Content PubMed PubMed Citation Articles by Tsui, J. K.C. Articles by Calne, D. B.

A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease

Division of Neurology. Department of Medicine, University Hospital, University of British Columbia, Vancouver, BC, Canada.

We carried out a double-blind rising dose study of a D-l dopamine agonist, CY 208-243, in 6 parkinsonian patients. Deficits monitored by Columbia scores were significantly improved at single doses ranging from 5 to 40 mg, though efficacy was low. Used alone, CY 208-243 was not a satisfactory therapeutic agent, and toxicity data precluded further increases in dosage.

Address correspondence and reprint requests to Dr. Tsui, Division of Neurology, Department of Medicine, University Hospital, University of British Columbia, Room S-129,2211 Wesbrook Mall, Vancouver, BC, V6T 1W5, Canada.

Received October 13, 1988. Accepted for publication in final form December 27, 1988.

This article has been cited by other articles:

				O. Rascol, J. G. Nutt, O. Blin, C. G. Goetz, J. M. Trugman, C. Soubrouillard, J. H. Carter, L. J. Currie, N. Fabre, C. Thalamas, et al. Induction by Dopamine D1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease Arch Neurol, February 1, 2001; 58(2): 249 - 254. [Abstract] [Full Text] [PDF]

				J. E. Ahlskog, M. D. Muenter, P. A. Bailey, and P. M. Stevens Dopamine Agonist Treatment of Fluctuating Parkinsonism: D-2 (Controlled-Release MK-458) vs Combined D-1 and D-2 (Pergolide) Arch Neurol, May 1, 1992; 49(5): 560 - 568. [Abstract] [PDF]